Abstract Number: 809 • 2018 ACR/ARHP Annual Meeting
The Lymphangiogenetic Factors VEGF-C, CCL21 and Ang-2 Are Associated with Pulmonary Arterial Hypertension in Systemic Sclerosis
Background/Purpose: Systemic sclerosis (SSc) is characterized by abnormalities in vascular pathways and lymphatic vessels with pulmonary hypertension as a major complication. Vascular endothelial growth factor…Abstract Number: 863 • 2018 ACR/ARHP Annual Meeting
Combining Cardiac Magnetic Resonance and Right Heart Catheterization to Evaluate Right Ventricular Function for the Prognosis Prediction in Patients with Connective Tissue Diseases and Pulmonary Hypertension
Background/Purpose: Pulmonary arterial hypertension associated with connective tissue diseases (CTD-PAH), particularly PAH associated with systemic sclerosis (SSc-PAH), has a poor prognosis compared with other PAH.…Abstract Number: 1743 • 2018 ACR/ARHP Annual Meeting
Serum Markers Potentially Associated with PAH in Systemic Sclerosis; A Targeted Screening Approach
Background/Purpose: Pulmonary arterial hypertension (PAH) is a feared complication in systemic sclerosis (SSc). Detection of PAH at a preclinical stage is important as early diagnosis…Abstract Number: 735 • 2017 ACR/ARHP Annual Meeting
Cardiopulmonary Exercise Testing to “Detect” Pulmonary Arterial Hypertension in Systemic Sclerosis
Background/Purpose: Pulmonary arterial hypertension (PAH) is one of the leading death causes in SSc patients. To gain a better prognosis, screening methods are needed to…Abstract Number: 743 • 2017 ACR/ARHP Annual Meeting
Impact of Detect on Right Heart Catheterization Referral and Results; Data from a Prospective, Unselected, Systemic Sclerosis Cohort
Background/Purpose: The DETECT calculator has been freely available as a tool for earlier detection and diagnosis of pulmonary arterial hypertension (PAH) in systemic sclerosis (SSc)…Abstract Number: 758 • 2017 ACR/ARHP Annual Meeting
Identification of Biomarkers Predictive of Pulmonary Arterial Hypertension in Systemic Sclerosis
Background/Purpose: Systemic sclerosis (SSc) is an autoimmune disease characterized by vascular abnormalities, immune system dysregulation, and fibrosis. Pulmonary arterial hypertension (PAH) affects approximately 10% of…Abstract Number: 1700 • 2017 ACR/ARHP Annual Meeting
Focusing on Pulmonary Vascular Disease at Early Stage of Systemic Sclerosis: Exercise-Induced Pulmonary Arterial Hypertension and Gene Co-Expression Networks Involved in Its Pathogenesis
Background/Purpose: Pulmonary arterial hypertension (PAH) is prominent as a vascular involvement in systemic sclerosis (SSc), which remains a leading cause of death in spite of…Abstract Number: 2683 • 2017 ACR/ARHP Annual Meeting
Factors Associated with Disease Progression in Early-Diagnosed Pulmonary Arterial Hypertension Associated with Systemic Sclerosis
Background/Purpose: Pulmonary arterial hypertension (PAH) is a severe complication of systemic sclerosis (SSc), and its diagnosis requires right heart catheterization (RHC). The DETECT study developed…Abstract Number: 835 • 2016 ACR/ARHP Annual Meeting
A Normal Pulmonary Diffusion Capacity Is Rare in Pulmonary Artery Hypertension in Systemic Sclerosis
Background/Purpose: Methods: Results: > 70% (mean 78%) versus 191 patients (94.6%) who had a low DLCO <70% (mean 39%). There was no difference…Abstract Number: 1884 • 2016 ACR/ARHP Annual Meeting
Esophageal Dilation and Interstitial Lung Disease Incidence and Progression in Systemic Sclerosis
Background/Purpose: Interstitial lung disease (ILD) is the leading cause of death in systemic sclerosis (SSc). Esophageal dysfunction and aspiration may play a role in SSc-ILD.…Abstract Number: 3246 • 2016 ACR/ARHP Annual Meeting
Predictors of Long-Term Outcomes in Systemic Sclerosis Associated Pulmonary Arterial Hypertension from the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma Registry
Background/Purpose: Pulmonary arterial hypertension (PAH) is a leading cause of death in patients with systemic sclerosis (SSc). Predictors of short-term mortality include male sex, age>60…Abstract Number: 3139 • 2015 ACR/ARHP Annual Meeting
Screening Algorithm for Pulmonary Hypertension in Systemic Sclerosis – Comparison of Predictive Accuracy of Three Algorithms
Background/Purpose: Pulmonary arterial hypertension (PAH) is the leading cause of mortality in systemic sclerosis (SSc), and is associated with a 3-year survival of approximately 50%.…Abstract Number: 2990 • 2015 ACR/ARHP Annual Meeting
Assessment of NT-Pro BNP As a Potential Marker for Pulmonary Hypertension in Systemic Sclerosis: Data from a Large, Prospective and Unselected Patient Cohort
Background/Purpose: In Systemic Sclerosis (SSc), pulmonary arterial hypertension (PAH) is often diagnosed at an advanced stage. Serum levels of N-terminal pro-brain natriuretic peptide (NT-proBNP) are…Abstract Number: 1720 • 2014 ACR/ARHP Annual Meeting
GATA6 Deficiency Activates UPR Pathways in Endothelial Cells during the Development of Pulmonary Arterial Hypertension
Background/Purpose: Pulmonary arterial hypertension (PAH) is a severe lung complication of systemic sclerosis (SSc), and accounts for a large proportion of SSc-related deaths. As a…Abstract Number: 1261 • 2014 ACR/ARHP Annual Meeting
Pulmonary Arterial Hypertension in Patients with Anti-PM-Scl Antibody
Background/Purpose: Patients with anti-PM-Scl antibody (PM-Scl) can present with several different phenotypes: polymyositis (PM), dermatomyositis (DM), systemic sclerosis (SSc), scleromyositis, or sclero-dermatomyositis. Pulmonary arterial hypertension…